دورية أكاديمية
أعرض في EDS

Perfluorocarbons in Research and Clinical Practice: A Narrative Review.

التفاصيل البيبلوغرافية
العنوان: Perfluorocarbons in Research and Clinical Practice: A Narrative Review.
المؤلفون: Nocentini G; From the Academic Department of Pediatrics (DPUO), Immune and Infectious Diseases Division, Research Unit of Primary Immunodeficiencies, IRCCS Bmbino Gesù Children's Hospital, Rome, Italy., MacLaren G; Cardiothoracic Intensive Care Unit, National University Health System, Singapore., Bartlett R; Department of Surgery, University of Michigan, Ann Arbor, Michigan., De Luca D; Division of Pediatrics and Neonatal Critical Care, 'A. Béclère' Medical Centre, Paris Saclay University Hospitals, APHP, Paris, France.; Physiopathology and Therapeutic Innovation Unit-INSERM U999, Paris Saclay University, Paris, France., Perdichizzi S; Pediatric Intensive Care Unit, Children's Hospital Bambino Gesù, IRCCS, Rome, Italy., Stoppa F; Pediatric Intensive Care Unit, Children's Hospital Bambino Gesù, IRCCS, Rome, Italy., Marano M; Pediatric Intensive Care Unit, Children's Hospital Bambino Gesù, IRCCS, Rome, Italy., Cecchetti C; Pediatric Intensive Care Unit, Children's Hospital Bambino Gesù, IRCCS, Rome, Italy., Biasucci DG; Department of Clinical Science and Translational Medicine, 'Tor Vergata' University of Rome, Rome, Italy., Polito A; Pediatric Intensive Care Unit, Department of Woman, Child, and Adolescent Medicine, Geneva University Hospital, Geneva, Switzerland., AlGhobaishi A; Pediatric Critical Care Unit, Department of Pediatrics, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia., Guner Y; Department of Pediatric Surgery, Children's Hospital of Orange County and University of California Irvine, Orange, California., Gowda SH; Departments of Surgery and Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas., Hirschl RB; Section of Pediatric Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan., Di Nardo M; Pediatric Intensive Care Unit, Children's Hospital Bambino Gesù, IRCCS, Rome, Italy.
المصدر: ASAIO journal (American Society for Artificial Internal Organs : 1992) [ASAIO J] 2023 Dec 01; Vol. 69 (12), pp. 1039-1048. Date of Electronic Publication: 2023 Aug 07.
نوع المنشور: Review; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9204109 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-943X (Electronic) Linking ISSN: 10582916 NLM ISO Abbreviation: ASAIO J Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Philadelphia, PA : Published for the Society by J.B. Lippincott Co., c1992-
مواضيع طبية MeSH: Fluorocarbons* , Blood Substitutes*/therapeutic use , Blood Substitutes*/chemistry, Emulsions ; Oxygen
مستخلص: Perfluorocarbons (PFCs) are organic liquids derived from hydrocarbons in which some of the hydrogen atoms have been replaced by fluorine atoms. They are chemically and biologically inert substances with a good safety profile. They are stable at room temperature, easy to store, and immiscible in water. Perfluorocarbons have been studied in biomedical research since 1960 for their unique properties as oxygen carriers. In particular, PFCs have been used for liquid ventilation in unusual environments such as deep-sea diving and simulations of zero gravity, and more recently for drug delivery and diagnostic imaging. Additionally, when delivered as emulsions, PFCs have been used as red blood cell substitutes. This narrative review will discuss the multifaceted utilization of PFCs in therapeutics, diagnostics, and research. We will specifically emphasize the potential role of PFCs as red blood cell substitutes, as airway mechanotransducers during artificial placenta procedures, as a means to improve donor organ perfusion during the ex vivo assessment, and as an adjunct in cancer therapies because of their ability to reduce local tissue hypoxia.
Competing Interests: Disclosure: M.D.N. is an advisory board member for Eurosets, Medolla Modena, Italy. The other authors have no conflicts of interest to report.
(Copyright © ASAIO 2023.)
References: Kylstra JA, Tissing MO, van der M: Of mice as fish. Trans Am Soc Artif Intern Organs. 8: 378–383, 1962.
Clark LC Jr, Gollan F: Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science. 152: 1755–1756, 1966.
Shaffer TH, Forman DL, Wolfson MR: Physiological effects of ventilation with liquid fluorocarbon at controlled temperatures. Undersea Biomed Res. 11: 287–298, 1984.
Greenspan JS, Wolfson MR, Rubenstein SD, Shaffer TH: Liquid ventilation of preterm baby. Lancet. 2: 1989, 1095.
Alapati D, Shaffer TH: Administration of drugs/gene products to the respiratory system: A historical perspective of the use of inert liquids. Front Physiol. 13: 871893, 2022.
Roberts TR, Harea GT, Singha P, et al.: Heparin-free extracorporeal life support using tethered liquid perfluorocarbon: A feasibility and efficacy study. ASAIO J. 66: 809–817, 2020.
Roberts TR, Choi JH, Wendorff DS, et al.: Tethered liquid perfluorocarbon coating for 72 hour heparin-free extracorporeal life support. ASAIO J. 67: 798–808, 2021.
Church JT, Coughlin MA, Perkins EM, et al.: The artificial placenta: Continued lung development during extracorporeal support in a preterm lamb model. J Pediatr Surg. 53: 1896–1903, 2018.
Gurunadh VS, Banarji A, Patyal S, et al.: Evaluation of vitreous substitutes in managing complicated vitreo-retinal surgeries. Med J Armed Forces India. 66: 125–128, 2010.
Lambert E, Gorantla VS, Janjic JM: Pharmaceutical design and development of perfluorocarbon nanocolloids for oxygen delivery in regenerative medicine. Nanomedicine (Lond). 14: 2697–2712, 2019.
Hill SE: Perfluorocarbons: Knowledge gained from clinical trials. Shock. 52: 60–64, 2019.
Davies M: Liquid ventilation. J Paediatr Child Health. 35: 434–437, 1999.
Shaffer TH, Wolfson MR, Greenspan JS: Liquid ventilation: Current status. Pediatr Rev. 20: e134–e142, 1999.
Greenspan JS, Wolfson MR, Shaffer TH: Liquid ventilation. Semin Perinatol. 24: 396–405, 2000.
Hirschl RB: Current experience with liquid ventilation. Paediatr Respir Rev. 5: S339–S345, 2004.
Kaisers U, Kelly KP, Busch T: Liquid ventilation. Br J Anaesth. 91: 143–151, 2003.
Wolfson MR, Shaffer TH: Pulmonary applications of perfluorochemical liquids: Ventilation and beyond. Paediatr Respir Rev. 6: 117–127, 2005.
Valls ISA, Alvarez FJ, Gastiasoro E: Liquid ventilation: From experimental use to clinical application. Biol Neonate. 80: 29–33, 2001.
Hamilton MC, Peek GJ, Dux AE: Partial liquid ventilation. Pediatr Radiol. 35: 1152–1156, 2005.
Eichenwald C, Dysart K, Zhang H, Fox W: Neonatal partial liquid ventilation for the treatment and prevention of bronchopulmonary dysplasia. Neoreviews. 21: e238–e248, 2020.
Voelker MT, Laudi S, Henkelmann J, Bercker S: Extracorporeal membrane oxygenation and perfluorocarbon in a therapy refractory case of acute respiratory distress syndrome. Ann Thorac Surg. 113: e355–e358, 2022.
Degnan AJ, Zhu X, Flowers C, Fox WW, Zhang H, Saul D: Imaging assessment of partial liquid ventilation in bronchopulmonary dysplasia. Curr Probl Diagn Radiol. 48: 247–250, 2019.
Von Neergaard D: Neue Auffassungen über ei nen Grundbegriff der Atemmechanik: Die Retraktionskraft der Lunge, abhänging von der Oberflächenspannung in den Alveolen. Z Gesamte Exp Med. 66: 373–394, 1929.
Fuhrman BP, Paczan PR, DeFrancisis M: Perfluorocarbonassociated gas exchange. Crit Care Med. 19: 712–722, 1991.
Kaushal A, McDonnell CG, Davies MW: Partial liquid ventilation for the prevention of mortality and morbidity in paediatric acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev. 2013: CD003845, 2013.
Wiedemann HP: Partial liquid ventilation for acute respiratory distress syndrome. Clin Chest Med. 21: 543–554, 2000.
Tawfic QA, Kausalya R: Liquid ventilation. Oman Med J. 26: 4–9, 2011.
Quintel M, Hirschl RB, Roth H, Loose R, van Ackern K: Computer tomographic assessment of perfluorocarbon and gas distribution during partial liquid ventilation for acute respiratory failure. Am J Respir Crit Care Med. 158: 249–255, 1998.
Kawamae K, Pristine G, Chiumello D, Tremblay LN, Slutsky AS: Partial liquid ventilation decreases serum tumor necrosis factor-alpha concentrations in a rat acid aspiration lung injury model. Crit Care Med. 28: 479–483, 2000.
von der Hardt K, Schoof E, Kandler MA, Dötsch J, Rascher W: Aerosolized perfluorocarbon suppresses early pulmonary inflammatory response in a surfactant-depleted piglet model. Pediatr Res. 51: 177–182, 2002.
Moskowitz GD, Shaffer TH, Dubin SE: Liquid breathing trials and animal studies with a demand-regulated liquid breathing system. Med Instrum. 9: 28–33, 1975.
Shaffer TH, Rubenstein D, Moskowitz D, Delivoria-Papadopoulos M: Gaseous exchange and acid-base balance in premature lambs during liquid ventilation since birth. Pediatr Res. 10: 227–231, 1976.
Shaffer TH, Tran N, Bhutani VK, Sivieri EM: Cardiopulmonary function in very preterm lambs during liquid ventilation. Pediatr Res. 17: 680–684, 1983.
Wolfson MR, Kechner NE, Roache RF, et al.: Perfluorochemical rescue after surfactant treatment: Effect of perflubron dose and ventilatory frequency. J Appl Physiol (1985). 84: 624–640, 1998.
Stavis RL, Wolfson MR, Cox C, Kechner N, Shaffer TH: Physiologic, biochemical, and histologic correlates associated with tidal liquid ventilation. Pediatr Res. 43: 132–138, 1998.
Greenspan JS, Cleary GM, Wolfson MR: Is liquid ventilation a reasonable alternative? Clin Perinatol. 25: 137–157, 1998.
Pranikoff T, Gauger PG, Hirschl RB: Partial liquid ventilation in newborn patients with congenital diaphragmatic hernia. J Pediatr Surg. 31: 613–618, 1996.
Leach CL, Greenspan JS, Rubenstein SD, et al.: Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. The LiquiVent Study Group. N Engl J Med. 335: 761–767, 1996.
Gauger PG, Pranikoff T, Schreiner RJ, Moler FW, Hirschl RB: Initial experience with partial liquid ventilation in pediatric patients with the acute respiratory distress syndrome. Crit Care Med. 24: 16–22, 1996.
Greenspan JS, Wolfson MR, Shaffer TH: Liquid ventilation: Clinical experiences. Biomed Instrum Technol. 33: 253–259, 1999.
Ricard JD, Lemaire F: Liquid ventilation. Curr Opin Crit Care. 7: 8–14, 2001.
Hirschl RB, Philip WF, Glick L, et al.: A prospective, randomized pilot trial of perfluorocarbon-induced lung growth in newborns with congenital diaphragmatic hernia. J Pediatr Surg. 38: 283–289; discussion 283, 2003.
Tiruvoipati R, Balasubramanian SK, Entwisle JJ, Firmin RK, Peek GJ: Pseudocalcification on chest CT scan. Br J Radiol. 80: e125–e127, 2007.
Mychaliska G, Bryner B, Dechert R, Kreutzman J, Becker M, Hirschl R: Safety and efficacy of perflubron-induced lung growth in neonates with congenital diaphragmatic hernia: Results of a prospective randomized trial. J Pediatr Surg. 50: 1083–1087, 2015.
Fedora M, Nekvasil R, Seda M, Klimovic M, Dominik P: Partial liquid ventilation in the therapy of pediatric acute respiratory distress syndrome. Bratisl Lek Listy. 100: 481–485, 1999.
Hirschl RB, Pranikoff T, Gauger P, Schreiner RJ, Dechert R, Bartlett RH: Liquid ventilation in adults, children, and full-term neonates. Lancet. 346: 1201–1202, 1995.
Hirschl RB, Pranikoff T, Wise C, et al.: Initial experience with partial liquid ventilation in adult patients with the acute respiratory distress syndrome. JAMA. 275: 383–389, 1996.
Hirschl RB, Croce M, Gore D, et al.: Prospective, randomized, controlled pilot study of partial liquid ventilation in adult acute respiratory distress syndrome. Am J Respir Crit Care Med. 165: 781–787, 2002.
Kacmarek RM, Wiedemann HP, Lavin PT, Wedel MK, Tütüncü AS, Slutsky AS: Partial liquid ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 173: 882–889, 2006.
Galvin IM, Steel A, Pinto R, Ferguson ND, Davies MW: Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev. 2013: CD003707, 2013.
Mitsuno T, Ohyanagi H, Naito R: Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA) summary of 186 cases. Ann Surg. 195: 60–69, 1982.
Spence RK, McCoy S, Costabile J, et al.: Fluosol DA-20 in the treatment of severe anemia: Randomized, controlled study of 46 patients. Crit Care Med. 18: 1227–1230, 1990.
Spahn DR, Waschke KF, Standl T, et al.; European Perflubron Emulsion in Non-Cardiac Surgery Study Group: Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: Results of a European phase 3 study. Anesthesiology. 97: 1338–1349, 2002.
Hill SE, Leone BJ, Faithfull NS, Flaim KE, Keipert PE, Newman MF: Perflubron emulsion (AF0144) augments harvesting of autologous blood: A phase II study in cardiac surgery. J Cardiothorac Vasc Anesth. 16: 555–560, 2002.
Pidcoke HF, Delacruz W, Herzig MC, et al.: Perfluorocarbons cause thrombocytopenia, changes in RBC morphology and death in a baboon model of systemic inflammation. PLoS One. 17: e0279694, 2022.
Deuchar GA, van Kralingen JC, Work LM, et al.: Preclinical validation of the therapeutic potential of glasgow oxygen level dependent (GOLD) technology: A theranostic for acute stroke. Transl Stroke Res. 10: 583–595, 2019.
Deuchar GA, Brennan D, Holmes WM, Shaw M, Macrae IM, Santosh C: Perfluorocarbon enhanced glasgow oxygen level dependent (GOLD) magnetic resonance metabolic imaging identifies the penumbra following acute ischemic stroke. Theranostics. 8: 1706–1722, 2018.
Boden K, Januschowski K, Szurman P: Heavy liquids as intraoperative instrument in retinal surgery. Ophthalmologe. 116: 930–939, 2019.
Lally KP: Congenital diaphragmatic hernia. Curr Opin Pediatr. 14: 486–490, 2002.
Wynn J, Krishnan U, Aspelund G, et al.: Outcomes of congenital diaphragmatic hernia in the modern era of management. J Pediatr. 163: 114–9.e1, 2013.
Greenspan JS, Fox WW, Rubenstein SD, Wolfson MR, Spinner SS, Shaffer TH: Partial liquid ventilation in critically ill infants receiving extracorporeal life support. Philadelphia Liquid Ventilation Consortium. Pediatrics. 99: E2, 1997.
Nobuhara KK, Fauza DO, DiFiore JW, et al.: Continuous intrapulmonary distension with perfluorocarbon accelerates neonatal (but not adult) lung growth. J Pediatr Surg. 33: 292–298, 1998.
Nobuhara KK, DiFiore JW, Ibla JC, et al.: Insulin-like growth factor-I gene expression in three models of accelerated lung growth. J Pediatr Surg. 33: 1057–1060; discussion 1061, 1998.
Fauza DO, Hirschl RB, Wilson JM: Continuous intrapulmonary distension with perfluorocarbon accelerates lung growth in infants with congenital diaphragmatic hernia: Initial experience. J Pediatr Surg. 36: 1237–1240, 2001.
Walker GM, Kasem KF, O’Toole SJ, Watt A, Skeoch CH, Davis CF: Early perfluorodecalin lung distension in infants with congenital diaphragmatic hernia. J Pediatr Surg. 38: 17–20; discussion 17, 2003.
Shah M, Phillips MR, Bryner B, Hirschl RB, Mychaliska GB, McLean SE: Effect of perflubron-induced lung growth on pulmonary vascular remodeling in congenital diaphragmatic hernia. Pediatr Surg Int. 32: 583–590, 2016.
Church JT, Perkins EM, Coughlin MA, et al.: Perfluorocarbons prevent lung injury and promote development during artificial placenta support in extremely premature lambs. Neonatology. 113: 313–321, 2018.
Larson AC, De Bie FR, Chang J, Davey MG, Flake AW: The EXTrauterine environment for neonatal development: Present and future. Pediatr Dev Pathol. 25: 253–262, 2022.
Fallon BP, Mychaliska GB: Development of an artificial placenta for support of premature infants: Narrative review of the history, recent milestones, and future innovation. Transl Pediatr. 10: 1470–1485, 2021.
Cox CA, Cullen AB, Wolfson MR, Shaffer TH: Intratracheal administration of perfluorochemical-gentamicin suspension: A comparison to intravenous administration in normal and injured lungs. Pediatr Pulmonol. 32: 142–151, 2001.
Jeng MJ, Lee YS, Soong WJ: Effects of perfluorochemicals for intrapulmonary vancomycin administration and partial liquid ventilation in an animal model of meconium-injured lungs. Acta Paediatr Taiwan. 48: 309–316, 2007.
Wolfson MR, Enkhbaatar P, Fukuda S, et al.: Perfluorochemical-facilitated plasminogen activator delivery to the airways: A novel treatment for inhalational smoke-induced acute lung injury. Clin Transl Med. 10: 258–274, 2020.
Weiss DJ, Bonneau L, Liggitt D: Use of perfluorochemical liquid allows earlier detection of gene expression and use of less vector in normal lung and enhances gene expression in acutely injured lung. Mol Ther. 3: 734–745, 2001.
Kazzaz JA, Strayer MS, Wu J, et al.: Perfluorochemical liquid-adenovirus suspensions enhance gene delivery to the distal lung. Pulm Med. 2011: 918036, 2011.
Chappell SE, Wolfson MR, Shaffer TH: A comparison of surfactant delivery with conventional mechanical ventilation and partial liquid ventilation in meconium aspiration injury. Respir Med. 95: 612–617, 2001.
Klein J, Faithfull NS, Salt PJ, Trouwborst A: Transperitoneal oxygenation with fluorocarbons. Anesth Analg. 65: 734–738, 1986.
Carr SR, Cantor JP, Rao AS, Lakshman TV, Collins JE, Friedberg JS: Peritoneal perfusion with oxygenated perfluorocarbon augments systemic oxygenation. Chest. 130: 402–411, 2006.
Van Raemdonck DE, Rega FR, Neyrinck AP, Jannis N, Verleden GM, Lerut TE: Non-heart-beating donors. Semin Thorac Cardiovasc Surg. 16: 309–321, 2004.
Inci I, Arni S, Iskender I, et al.: Functional, metabolic and morphologic results of ex vivo donor lung perfusion with a perfluorocarbon-based oxygen carrier nanoemulsion in a large animal transplantation model. Cells. 9: 2501, 2020.
Spahn DR: Artificial oxygen carriers: A new future? Crit Care. 22: 46, 2018.
Fontes P, Lopez R, van der Plaats A, et al.: Liver preservation with machine perfusion and a newly developed cell-free oxygen carrier solution under subnormothermic conditions. Am J Transplant. 15: 381–394, 2015.
Bhattacharjee RN, Patel SVB, Sun Q, et al.: Renal protection against ischemia reperfusion injury: Hemoglobin-based oxygen carrier-201 versus blood as an oxygen carrier in ex vivo subnormothermic machine perfusion. Transplantation. 104: 482–489, 2020.
Gamal-Eldeen AM, Alrehaili AA, Alharthi A, Raafat BM: Perftoran (®) inhibits hypoxia-associated resistance in lung cancer cells to carboplatin. Front Pharmacol. 13, 2022. doi:10.3389/fphar.2022.860898.
Graham K, Unger E: Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine. 13: 6049–6058, 2018.
Krafft MP: Alleviating tumor hypoxia with perfluorocarbon-based oxygen carriers. Curr Opin Pharmacol. 53: 117–125, 2020.
Song X, Feng L, Liang C, Yang K, Liu Z: Ultrasound triggered tumor oxygenation with oxygen-shuttle nanoperfluorocarbon to overcome hypoxia-associated resistance in cancer therapies. Nano Lett. 16: 6145–6153, 2016.
Zhou Z, Zhang B, Wang H, Yuan A, Hu Y, Wu J: Two-stage oxygen delivery for enhanced radiotherapy by perfluorocarbon nanoparticles. Theranostics. 8: 4898–4911, 2018.
Xiang Y, Bernards N, Hoang B, Zheng J, Matsuura N: Perfluorocarbon nanodroplets can reoxygenate hypoxic tumors in vivo without carbogen breathing. Nanotheranostics. 3: 135–144, 2019.
Song D, Beringhs AO, Zhuang Z, et al.: Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging. Nanotheranostics. 3: 223–235, 2019.
Choi MR, Stanton-Maxey KJ, Stanley JK, et al.: A cellular Trojan Horse for delivery of therapeutic nanoparticles into tumors. Nano Lett. 7: 3759–3765, 2007.
Huang WC, Chiang WH, Cheng YH, et al.: Tumortropic monocyte-mediated delivery of echogenic polymer bubbles and therapeutic vesicles for chemotherapy of tumor hypoxia. Biomaterials. 71: 71–83, 2015.
سلسلة جزيئية: ClinicalTrials.gov NCT03041740
المشرفين على المادة: 0 (Fluorocarbons)
0 (Blood Substitutes)
0 (Emulsions)
S88TT14065 (Oxygen)
تواريخ الأحداث: Date Created: 20230807 Date Completed: 20231204 Latest Revision: 20231222
رمز التحديث: 20231222
DOI: 10.1097/MAT.0000000000002017
PMID: 37549675
قاعدة البيانات: MEDLINE
الوصف
تدمد:1538-943X
DOI:10.1097/MAT.0000000000002017